The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: A population-based study

Cancer

Volumn 106, Issue 9, 2006, Pages 2058-2066

  Seve, Pascal ^a,b   Sawyer, Michael ^b   Hanson, John ^b   Broussolle, Christiane ^a   Dumontet, Charles ^c   Mackey, John R ^b,d  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

Age; Cancer of unknown primary site; Comorbidities; Performance status

Indexed keywords

ADULT; ADULT COMORBIDITY EVALUATION 27; AGE; AGED; ARTICLE; CANADA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COMORBIDITY; DRUG CHOICE; EXTERNAL BIAS; FEMALE; FUNCTIONAL STATUS; GENDER; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PATIENT REFERRAL; PLEURA METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TERTIARY HEALTH CARE; TUMOR LOCALIZATION; UNKNOWN PRIMARY SITE CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 33646345121     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21833     Document Type: Article

References (32)

1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.
2. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257-263.
3. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-553.
4. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003;89(Suppl 1):S59-S66.
5. Greco FA, Hainsworth JD. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Semin Oncol. 1999;26:129-133.
6. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a Phase II Hellenic Cooperative Oncology Group study. J Clin Oncol. 2000;18:3101-3107.
7. Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.
8. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280.
9. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38:409-413.
10. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer. 2002;38:1810-1812.
11. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679-4683.
12. [No authors listed.] NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. Oncology (Huntington). 1998;12:226-309.
13. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-2447.
14. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593-602.
15. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885-892.
16. Albertsen P. When is a death from prostate cancer not a death from prostate cancer? J Natl Cancer Inst 2000;92:590-591.
17. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-2134.
18. Truong PT, Kader HA, Lacy B, et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol. 2005;28:157-164.
19. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
20. de Rijke JM, Schouten LJ, ten Velde GP, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004;46:233-245.
21. Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005;41:779-785.
22. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
23. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243-250.
24. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998;53:M372-M378.
25. Vaeth PA, Satariano WA, Ragland DR. Limiting comorbid conditions and breast cancer stage at diagnosis. J Gerontol A Biol Sci Med Sci. 2000;55:M593-M600.
26. de Rijke JM, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, van den Brandt PA. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the Province of Limburg, the Netherlands. Ann Oncol. 1996;7:677-685.
27. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Coebergh JW. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res. 2005;124:89-107.
28. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol. 2004;22:4971-4978.
29. Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW. Adjuvant treatment for elderly patients with Stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005;16:767-772.
30. Hillen HF. Unknown primary tumours. Postgrad Med J. 2000;76:690-693.
31. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.
32. Schrijvers CT, Coebergh JW, Mackenbach JP. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 1997;80:1482-1488.